Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ:OLMA
Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$16.82
$0.55(10.50%)
At close: 4:00 PM EST
$16.82
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$4.02 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.47M
Market Cap
$830.67M
Enterprise Value$772.97M
Total Cash (Recent Filing)$505.35M
Total Debt (Recent Filing)$956.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 11, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding87,347,470
10 Day Avg. Volume1,741,087
30 Day Avg. Volume1,465,585
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.53K
Enterprise Value/Ebitda-4.19
Forecast
1Y Price Target
$38.14Price Target Upside126.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$2.25M
Bulls Say, Bears Say
Bulls Say
Strategic Collaboration With BayerA clinical collaboration with Bayer for OP-3136 is a durable strategic win: it brings a large partner into combination development, supplies a complementary agent, shares clinical data while leaving Olema commercialization rights, and materially broadens indication and partnership optionality across solid tumors.
Encouraging Phase 1 OP-3136 DataPreliminary Phase 1 results showing tolerability, clear target engagement, and tumor shrinkage in a heavily pretreated cohort provide structural clinical validation. Durable implication: a favorable safety/efficacy profile supports combination strategies, regulatory pathing, and increased probability for advancing OP-3136.
Low Leverage, Growing Equity BaseVery low debt reduces refinancing and interest risks and provides financial flexibility during the clinical development window. The sizeable, growing equity base supports continued R&D investment and optionality for partnerships or bolt-on programs without immediate solvency pressure.
Bears Say
Pre-revenue ProfileBeing pre-revenue is a durable constraint: until commercialization or sustained partner royalties, the company lacks internal revenue to fund operations. This means long-term financing dependence, makes operating leverage zero, and keeps cash returns and profit metrics unattractive for the foreseeable development horizon.
High And Worsening Cash BurnPersistently negative and worsening operating and free cash flow signal a high structural burn rate that will necessitate further financing before commercialization. This increases dilution risk, compresses runway timing for trials, and forces management to balance development pace against capital markets access.
Shareholder Dilution & Negative ROEMaterial negative ROE and explicit dilution risk indicate that existing equity is being eroded by ongoing losses. Over the medium term, this structurally raises the probability of additional equity financings, potential investor dilution, and constrained incentives for long-term equity holders absent a value-inflecting clinical or commercial event.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?
Olema Pharmaceuticals, Inc. lowest stock price was $4.02 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals, Inc.’s market cap?
Olema Pharmaceuticals, Inc.’s market cap is $830.67M.
When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?
Olema Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Olema Pharmaceuticals, Inc.’s earnings last quarter?
Olema Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.011.
Is Olema Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Olema Pharmaceuticals, Inc. pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
What is Olema Pharmaceuticals, Inc.’s EPS estimate?
Olema Pharmaceuticals, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Olema Pharmaceuticals, Inc. have?
Olema Pharmaceuticals, Inc. has 87,347,470 shares outstanding.
What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?
Olema Pharmaceuticals, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went down -5.989%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.14 (126.77% Upside)
$38.14 (126.77% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
131.95%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
29.54%
Trailing 12-Months
Company Description
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
OLMA Stock 12 Month Forecast
Average Price Target
$38.14
▲(126.77% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
2.67% Insiders
20.32% Mutual Funds
61.04% Other Institutional Investors
2.53% Public Companies and Individual Investors